CN1227233C - 纯晶形的5－氯－3－(4－甲磺酰基苯基)－6′－甲基－[2,3′]联吡啶及其合成方法 - Google Patents

纯晶形的5－氯－3－(4－甲磺酰基苯基)－6′－甲基－[2,3′]联吡啶及其合成方法 Download PDF

Info

Publication number
CN1227233C
CN1227233C CNB018101372A CN01810137A CN1227233C CN 1227233 C CN1227233 C CN 1227233C CN B018101372 A CNB018101372 A CN B018101372A CN 01810137 A CN01810137 A CN 01810137A CN 1227233 C CN1227233 C CN 1227233C
Authority
CN
China
Prior art keywords
polymorphic form
disease
type
compound
purposes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
CNB018101372A
Other languages
English (en)
Chinese (zh)
Other versions
CN1443168A (zh
Inventor
L·S·克罗克尔
I·W·戴维斯
R·G·奥斯夫钦
A·科特利尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22772880&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1227233(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of CN1443168A publication Critical patent/CN1443168A/zh
Application granted granted Critical
Publication of CN1227233C publication Critical patent/CN1227233C/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CNB018101372A 2000-05-26 2001-05-22 纯晶形的5－氯－3－(4－甲磺酰基苯基)－6′－甲基－[2,3′]联吡啶及其合成方法 Ceased CN1227233C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20801700P 2000-05-26 2000-05-26
US60/208,017 2000-05-26

Publications (2)

Publication Number Publication Date
CN1443168A CN1443168A (zh) 2003-09-17
CN1227233C true CN1227233C (zh) 2005-11-16

Family

ID=22772880

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018101372A Ceased CN1227233C (zh) 2000-05-26 2001-05-22 纯晶形的5－氯－3－(4－甲磺酰基苯基)－6′－甲基－[2,3′]联吡啶及其合成方法

Country Status (48)

Country Link
EP (1) EP1296951B1 (enExample)
JP (2) JP3665053B2 (enExample)
KR (1) KR100757699B1 (enExample)
CN (1) CN1227233C (enExample)
AR (1) AR028577A1 (enExample)
AT (1) ATE483687T1 (enExample)
AU (2) AU6480401A (enExample)
BG (1) BG65855B1 (enExample)
BR (1) BRPI0111140B8 (enExample)
CA (1) CA2410234C (enExample)
CR (1) CR6606A (enExample)
CY (1) CY1111440T1 (enExample)
CZ (1) CZ20023888A3 (enExample)
DE (1) DE60143197D1 (enExample)
DK (1) DK1296951T3 (enExample)
EA (1) EA004809B1 (enExample)
EE (1) EE05242B1 (enExample)
EG (1) EG24189A (enExample)
ES (1) ES2351958T3 (enExample)
GC (1) GC0000362A (enExample)
GE (1) GEP20053492B (enExample)
GT (1) GT200100091A (enExample)
HN (1) HN2001000110A (enExample)
HR (1) HRP20020934B1 (enExample)
HU (1) HU228423B1 (enExample)
IL (1) IL152582A0 (enExample)
IN (2) IN2002CH02089A (enExample)
IS (1) IS2806B (enExample)
JO (1) JO2216B1 (enExample)
MA (1) MA26919A1 (enExample)
ME (1) ME00428B (enExample)
MX (1) MX230696B (enExample)
MY (1) MY123569A (enExample)
NO (1) NO324495B1 (enExample)
NZ (1) NZ522394A (enExample)
PA (1) PA8516901A1 (enExample)
PE (1) PE20011324A1 (enExample)
PH (1) PH12001001175B1 (enExample)
PL (1) PL358153A1 (enExample)
PT (1) PT1296951E (enExample)
RS (1) RS51541B (enExample)
SI (1) SI1296951T1 (enExample)
SK (1) SK287174B6 (enExample)
SV (1) SV2002000462A (enExample)
TW (1) TWI303634B (enExample)
UA (1) UA73355C2 (enExample)
WO (1) WO2001092230A1 (enExample)
ZA (1) ZA200209558B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107417600A (zh) * 2017-09-26 2017-12-01 江苏正大清江制药有限公司 一种依托考昔与呋喃甲酸形成盐的新晶型及制备方法

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858631B1 (en) 1999-11-29 2005-02-22 Merck & Co., Inc. Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl
DK1248618T3 (da) 1999-11-29 2006-07-10 Merck Frosst Canada Inc Polymorfe, amorfe og hydratiserede former af 5-chlor-3-(4-methansulfonylphenyl)-6'-methyl-[2,3']bipyridinyl
US6521642B2 (en) * 2000-05-26 2003-02-18 Merck & Co., Inc. 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl in pure crystalline form and process for synthesis
DK2479166T3 (da) 2009-02-27 2014-09-01 Cadila Healthcare Ltd Fremgangsmåde til fremstilling af etoricoxib
WO2012004677A1 (en) 2010-07-05 2012-01-12 Actavis Group Ptc Ehf Solid state forms of etoricoxib salts
WO2012163839A1 (en) 2011-05-27 2012-12-06 Farma Grs, D.O.O. A process for the preparation of polymorphic form i of etoricoxib
WO2013105106A1 (en) 2011-11-03 2013-07-18 Cadila Healthcare Limited An improved process for the preparation of etoricoxib and polymorphs thereof
WO2013075732A1 (en) 2011-11-21 2013-05-30 Synthon Bv Process for making crystalline form i of etoricoxib
EP2601952A1 (en) 2011-12-07 2013-06-12 Zentiva, k.s. Novel pharmaceutically acceptable salts and cocrystals of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl and their therapeutic uses
PL2887924T3 (pl) 2012-08-27 2017-09-29 Cadila Healthcare Limited Kompozycje farmaceutyczne etorykoksybu
WO2014041558A2 (en) * 2012-08-27 2014-03-20 Glenmark Pharmaceuticals Limited; Glenmark Generics Limited Process for preparation of crystalline etoricoxib
CN104418799A (zh) * 2013-09-03 2015-03-18 天津药物研究院 一种依托考昔的晶型及其制备方法和应用
WO2015036550A1 (en) 2013-09-13 2015-03-19 Synthon B.V. Process for making etoricoxib
CN106632003B (zh) * 2015-12-31 2019-02-12 上海博志研新药物技术有限公司 一种依托考昔的制备方法
CN108069896B (zh) * 2016-11-11 2022-08-12 昆明积大制药股份有限公司 一种依托考昔晶型的制备方法
CN107417599B (zh) * 2017-06-21 2020-06-09 四川尚锐生物医药有限公司 一种依托考昔晶型的制备方法
CN107056691B (zh) * 2017-06-21 2020-03-10 四川尚锐生物医药有限公司 一种制备依托考昔晶型v的方法
MX2017009660A (es) 2017-07-26 2017-11-23 Laboratorios Liomont S A De C V Composicion farmaceutica con un rango de relacion entre el clorhidrato de tramadol y el etoricoxib para su administracion para el tratamiento del dolor.
CN107556231A (zh) * 2017-09-23 2018-01-09 江苏正大清江制药有限公司 一种依托考昔与对硝基苯甲酸形成的盐的晶型及制备方法
CN107898787B (zh) * 2017-12-15 2018-11-30 扬子江药业集团上海海尼药业有限公司 一种药物组合物及其制剂和制备方法
MX2018013070A (es) 2017-12-29 2019-10-15 Gruenenthal Gmbh Combinación farmacéutica que comprende clorhidrato de tramadol de liberación extendida y etoricoxib de liberación inmediata, y su uso para el tratamiento del dolor.
CN110143915A (zh) * 2019-06-03 2019-08-20 蚌埠学院 一种依托考昔与对甲苯磺酸形成盐的新晶型及制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593994A (en) * 1994-09-29 1997-01-14 The Dupont Merck Pharmaceutical Company Prostaglandin synthase inhibitors
US5739166A (en) * 1994-11-29 1998-04-14 G.D. Searle & Co. Substituted terphenyl compounds for the treatment of inflammation
CZ292843B6 (cs) * 1996-07-18 2003-12-17 Merck Frosst Canada & Co. Derivát pyridinu a farmaceutický prostředek s jeho obsahem
US5861419A (en) * 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
EP1071745B1 (en) * 1998-04-24 2004-08-04 Merck & Co., Inc. Process for synthesizing cox-2 inhibitors
DK1248618T3 (da) * 1999-11-29 2006-07-10 Merck Frosst Canada Inc Polymorfe, amorfe og hydratiserede former af 5-chlor-3-(4-methansulfonylphenyl)-6'-methyl-[2,3']bipyridinyl

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107417600A (zh) * 2017-09-26 2017-12-01 江苏正大清江制药有限公司 一种依托考昔与呋喃甲酸形成盐的新晶型及制备方法

Also Published As

Publication number Publication date
RS51541B (sr) 2011-06-30
IS2806B (is) 2012-09-15
CA2410234C (en) 2008-05-13
HUP0302336A2 (hu) 2003-11-28
EP1296951A1 (en) 2003-04-02
HRP20020934B1 (en) 2012-01-31
PE20011324A1 (es) 2002-01-28
HK1058932A1 (en) 2004-06-11
CZ20023888A3 (cs) 2003-02-12
PT1296951E (pt) 2010-12-07
JP2004501116A (ja) 2004-01-15
GEP20053492B (en) 2005-04-25
MA26919A1 (fr) 2004-12-20
CA2410234A1 (en) 2001-12-06
JP4142621B2 (ja) 2008-09-03
SI1296951T1 (sl) 2011-01-31
NZ522394A (en) 2004-05-28
EG24189A (en) 2008-10-08
NO20025674D0 (no) 2002-11-26
JP3665053B2 (ja) 2005-06-29
IL152582A0 (en) 2003-05-29
HN2001000110A (es) 2002-03-06
EA004809B1 (ru) 2004-08-26
ES2351958T3 (es) 2011-02-14
NO324495B1 (no) 2007-10-29
ATE483687T1 (de) 2010-10-15
ME00428B (me) 2011-10-10
CR6606A (es) 2006-02-06
EE200200655A (et) 2004-08-16
HU228423B1 (en) 2013-03-28
AR028577A1 (es) 2003-05-14
AU2001264804B2 (en) 2006-04-06
TWI303634B (en) 2008-12-01
YU89402A (sh) 2005-11-28
DK1296951T3 (da) 2011-01-24
KR100757699B1 (ko) 2007-09-13
BRPI0111140B1 (pt) 2018-03-13
JO2216B1 (en) 2004-10-07
SV2002000462A (es) 2002-03-08
NO20025674L (no) 2002-11-26
GT200100091A (es) 2001-12-28
WO2001092230A1 (en) 2001-12-06
IN2002CH02089A (enExample) 2005-02-25
UA73355C2 (en) 2005-07-15
HRP20020934A2 (en) 2005-02-28
MY123569A (en) 2006-05-31
EP1296951B1 (en) 2010-10-06
BR0111140A (pt) 2005-01-11
PH12001001175B1 (en) 2006-08-10
AU6480401A (en) 2001-12-11
EE05242B1 (et) 2009-12-15
BG107237A (bg) 2003-05-30
CY1111440T1 (el) 2015-08-05
DE60143197D1 (de) 2010-11-18
JP2005047927A (ja) 2005-02-24
KR20030003762A (ko) 2003-01-10
SK287174B6 (sk) 2010-02-08
IS6630A (is) 2002-11-20
BRPI0111140B8 (pt) 2021-05-25
PL358153A1 (en) 2004-08-09
MXPA02011619A (es) 2003-03-27
MX230696B (es) 2005-09-19
EA200201264A1 (ru) 2003-04-24
IN2007CH05103A (enExample) 2008-08-27
CN1443168A (zh) 2003-09-17
ZA200209558B (en) 2003-10-28
SK16702002A3 (sk) 2003-05-02
PA8516901A1 (es) 2002-04-25
BG65855B1 (bg) 2010-03-31
GC0000362A (en) 2007-03-31

Similar Documents

Publication Publication Date Title
CN1227233C (zh) 纯晶形的5－氯－3－(4－甲磺酰基苯基)－6′－甲基－[2,3′]联吡啶及其合成方法
JP7145931B2 (ja) 化合物の結晶多形、その製造方法及び用途
JP2009537603A (ja) ５−アミノ−３−（２’，３’−ジ−Ｏ−アセチル−ベータ−Ｄ−リボフラノシル）−３Ｈ−チアゾロ［４，５−ｄ］ピリミジン−２−オンのマレイン酸塩のＡ型及びＢ型結晶形
CN1128261A (zh) 制备具有两种晶形的四唑衍生物的方法及所述衍生物的新晶形
AU2001264804A1 (en) 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- [2,3']bipyridinyl in pure crystalline form and process for synthesis
JP2012500819A5 (enExample)
US6673935B2 (en) 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl in pure crystalline form and process for synthesis
AU2001292907A1 (en) 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl in pure crystalline form and process for synthesis
HK1040078A1 (en) Crystal forms of 3-(2,4-dichlorobenzyl)-2-methyl-n-(pentylsulfonyl)-3h-benzimidazole-5-carboxamide
US6800647B2 (en) 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3]bipyridinyl in pure crystalline form and process for synthesis
HK1058932B (en) 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl in pure crystalline form and process for synthesis
JP2011105649A (ja) アゼルニジピンの結晶
WO2019037591A1 (zh) 盐酸美法仑晶型及其制备方法与应用
CN1694884A (zh) Ⅰ晶型、ⅱ晶型、ⅲ晶型泛昔洛韦及其制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1058932

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: MERCK & CO. INC.

Free format text: FORMER NAME OR ADDRESS: MERCK + CO., INC.

CP01 Change in the name or title of a patent holder

Address after: New jersey, USA

Patentee after: MERCK & Co.,Inc.

Address before: New jersey, USA

Patentee before: MERCK & Co.,Inc.

C56 Change in the name or address of the patentee

Owner name: MERCK + CO INC

Free format text: FORMER NAME: MERCK + CO

CP01 Change in the name or title of a patent holder

Address after: New jersey, USA

Patentee after: MERCK SHARP & DOHME Corp.

Address before: New jersey, USA

Patentee before: MERCK & Co.,Inc.

ASS Succession or assignment of patent right

Owner name: SCHERING CORP (US)

Free format text: FORMER OWNER: MSD CORP.

Effective date: 20121025

C41 Transfer of patent application or patent right or utility model
C56 Change in the name or address of the patentee

Owner name: MSD CORP.

Free format text: FORMER NAME: SCHERING CORP (US)

CP01 Change in the name or title of a patent holder

Address after: New jersey, USA

Patentee after: MERCK SHARP & DOHME Corp.

Address before: New jersey, USA

Patentee before: SCHERING Corp.

TR01 Transfer of patent right

Effective date of registration: 20121025

Address after: New jersey, USA

Patentee after: SCHERING Corp.

Address before: New jersey, USA

Patentee before: MERCK SHARP & DOHME Corp.

IW01 Full invalidation of patent right

Decision date of declaring invalidation: 20190418

Decision number of declaring invalidation: 39824

Granted publication date: 20051116

IW01 Full invalidation of patent right